376138.fig.001a
(a)
376138.fig.001b
(b)
376138.fig.001c
(c)
376138.fig.001d
(d)
376138.fig.001e
(e)
376138.fig.001f
(f)
376138.fig.001g
(g)
376138.fig.001h
(h)
376138.fig.001i
(i)
376138.fig.001j
(j)
376138.fig.001k
(k)
376138.fig.001l
(l)
376138.fig.001m
(m)
376138.fig.001n
(n)
376138.fig.001o
(o)
Figure 1: Effect of EB101 vaccine on beta amyloid (Aβ) deposits in the brains of B6C3F1/J mice. Comparative photomicrographs of Aβ immunoreactivity were taken in the hippocampus ((a)–(k), (m), (n)) and cortical ((l), (o)) brain regions of transgenic mice treated with the vaccine (Grp A) before Aβ plaques develop preventive treatment ((a)–(i)) and after the Aβ plaques developed therapeutic treatment ((j)–(o)). Preventive Treatment: Transverse brain sections of 11-month-old mice show almost complete absence of Aβ deposits in the dentate gyrus ((a)–(c)) and hippocampal subregion CA1 following EB101 vaccine immunization (group A), contrasting sharply with the numerous Aβ immunoreactive plaques in the corresponding mouse brain sections treated with EB102 (group B in (d)–(f)) or PBS (group C in (g)–(i)). Immunoreactive Aβ in the brain sections of wild-type mice is absent (inserts in (g)–(i)). Therapeutic Treatment: Transverse brain sections of 18-month-old mice are shown in (j)–(o). Treatment with EB101 almost completely abolished Aβ load in the retrosplenial cortex/hippocampal subregion CA1 ((j)–(k)) and ectorhinal cortex (l) compared to the same areas of mice treated with EB102 ((m)–(o)), as determined by number of plaques and staining intensity area. Scale bar: 100 μm.